Transcode Change To Netincome from 2010 to 2025

RNAZ Stock  USD 4.29  2.49  36.73%   
Transcode Therapeutics Change To Netincome yearly trend continues to be fairly stable with very little volatility. Change To Netincome will likely drop to about 764.7 K in 2025. During the period from 2010 to 2025, Transcode Therapeutics Change To Netincome regression line of annual values had r-squared of  0.59 and arithmetic mean of  466,592. View All Fundamentals
 
Change To Netincome  
First Reported
2010-12-31
Previous Quarter
1.2 M
Current Value
764.7 K
Quarterly Volatility
544.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 55.3 K, Tax Provision of 0.0 or Net Interest Income of 17.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.42. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' Change To Netincome Growth Pattern

Below is the plot of the Change To Netincome of Transcode Therapeutics over the last few years. It is Transcode Therapeutics' Change To Netincome historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change To Netincome10 Years Trend
Slightly volatile
   Change To Netincome   
       Timeline  

Transcode Change To Netincome Regression Statistics

Arithmetic Mean466,592
Geometric Mean201,787
Coefficient Of Variation116.65
Mean Deviation491,265
Median70,266
Standard Deviation544,268
Sample Variance296.2B
Range1.5M
R-Value0.77
Mean Square Error129.7B
R-Squared0.59
Significance0.0005
Slope87,908
Total Sum of Squares4.4T

Transcode Change To Netincome History

2025764.7 K
20241.2 M
20211.1 M
20201.5 M
2019103.4 K

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Change To Netincome, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change To Netincome1.2 M764.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.